← Back to Screener
Veru Inc. (VERU)
Price$2.43
Favorite Metrics
Price vs S&P 500 (26W)-46.66%
Price vs S&P 500 (4W)-2.00%
Market Capitalization$39.00M
All Metrics
Book Value / Share (Quarterly)$2.31
P/TBV (Annual)3.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.92%
Cash Flow / Share (Quarterly)$-1.55
Price vs S&P 500 (YTD)9.88%
Gross Margin (TTM)34.66%
Net Profit Margin (TTM)-223.86%
EPS (TTM)$-1.20
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.20
Revenue Growth (5Y)-11.89%
EPS (Annual)$-2.80
ROI (Annual)-89.59%
Gross Margin (Annual)34.67%
Net Profit Margin (5Y Avg)-208.17%
Cash / Share (Quarterly)$2.21
Revenue Growth QoQ (YoY)72.36%
ROA (Last FY)-62.57%
Revenue Growth TTM (YoY)3.62%
EBITD / Share (TTM)$-1.19
ROE (5Y Avg)-150.44%
Operating Margin (TTM)-218.61%
Cash Flow / Share (Annual)$-2.05
P/B Ratio1.05x
P/B Ratio (Quarterly)0.93x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)0.36x
Net Interest Coverage (TTM)-42.80x
ROA (TTM)-55.64%
EV / EBITDA (TTM)0.46x
EPS Incl Extra (Annual)$-2.80
Current Ratio (Annual)2.43x
Quick Ratio (Quarterly)4.97x
3-Month Avg Trading Volume0.11M
52-Week Price Return-53.52%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.21
P/S Ratio (Annual)2.31x
Asset Turnover (Annual)0.28x
52-Week High$7.40
Operating Margin (5Y Avg)-203.80%
EPS Excl Extra (Annual)$-2.80
CapEx CAGR (5Y)-60.34%
Tangible BV CAGR (5Y)21.71%
26-Week Price Return-37.91%
Quick Ratio (Annual)2.35x
13-Week Price Return4.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.16x
Enterprise Value$6.011
Revenue / Share Growth (5Y)20.05%
Asset Turnover (TTM)0.24x
Book Value / Share Growth (5Y)23.78%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-219.56%
Cash / Share (Annual)$1.25
3-Month Return Std Dev54.25%
Gross Margin (5Y Avg)61.87%
Net Income / Employee (TTM)$-1
ROE (Last FY)-116.97%
Net Interest Coverage (Annual)-42.83x
EPS Basic Excl Extra (Annual)$-2.80
P/FCF (TTM)9.82x
Receivables Turnover (TTM)3.99x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.20
Receivables Turnover (Annual)3.99x
ROI (TTM)-83.24%
P/S Ratio (TTM)2.31x
Pretax Margin (5Y Avg)-208.12%
Revenue / Share (Annual)$1.25
Tangible BV / Share (Annual)$2.21
Price vs S&P 500 (52W)-88.62%
Year-to-Date Return14.02%
5-Day Price Return2.52%
EPS Normalized (Annual)$-2.80
ROA (5Y Avg)-68.61%
Net Profit Margin (Annual)-223.86%
Month-to-Date Return10.41%
Cash Flow / Share (TTM)$-1.49
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-218.61%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-107.33%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.20
P/TBV (Quarterly)3.48x
P/B Ratio (Annual)3.04x
Inventory Turnover (TTM)2.04x
Pretax Margin (TTM)-219.56%
Book Value / Share (Annual)$1.25
Price vs S&P 500 (13W)1.41%
Beta-1.11x
P/FCF (Annual)45.88x
Revenue / Share (TTM)$1.15
ROE (TTM)-83.24%
52-Week Low$2.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VERUVeru Inc. | 2.31x | 3.62% | 34.66% | — | $2.43 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Veru is a late-stage biopharmaceutical developing therapies for cardiometabolic and inflammatory diseases. Enobosarm, a selective androgen receptor modulator, is in Phase 2b development for obesity to enhance fat loss selectivity when combined with GLP-1 RA drugs. Sabizabulin, an oral microtubule disruptor, is advancing to Phase 2 trials for atherosclerotic cardiovascular disease to reduce inflammation and high-sensitivity CRP levels.